In this double blind trial conducted from September 2006 to May 2007 in the Czech Republic and Finland, participants aged 18–64 years were randomized to receive 1 dose of TIV ( ) or placebo ( ). Influenza like illnesses (ILI) were identified.
The attack rate for culture confirmed ILI was 3.2% in the placebo group. Vaccine efficacy against culture confirmed influenza A and/or B due to strains antigenically matched to the vaccine was 66.9% and to any strain was 61.6%.
TIV is efficacious against culture confirmed influenza in healthy adults.